While all clinically available PPIs were found to have the anti‐inflammatory activity, we particularly confirmed that OM was effective in inhibiting the activation of NF‐κB/AP‐1 and IRF in TLR4 signaling cascades and reducing pro‐inflammatory cytokine production, including IL‐6, TNF‐α, and MCP‐1, in THP‐1 cell‐derived macrophages and human PBMC. The gene discussed is CCL2; the disease is ocular melanoma.